COMMUNIQUÉS West-GlobeNewswire
-
Alimera Sciences Announces Clinical Data Featuring the Benefits of ILUVIEN® to be Presented at the American Academy of Ophthalmology Annual Meeting
01/10/2019 - 14:00 -
GBT to Host Analyst & Investor Day on October 8 in New York
01/10/2019 - 14:00 -
Immunomedics to Present at the 2019 Cantor Global Healthcare Conference
01/10/2019 - 14:00 -
Editas Medicine to Participate in Upcoming Investor Conferences
01/10/2019 - 14:00 -
Progressive Care Inc. Announces Formation of RXMD Therapeutics Inc. Specializing in Cannabinoid-Based and Alternative Nutraceutical Products
01/10/2019 - 14:00 -
Biogen Announces Leadership Update
01/10/2019 - 14:00 -
Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer
01/10/2019 - 14:00 -
Vaxart to Present Clinical Data From its Norovirus Phase 1b Study at Three Global Healthcare Conferences in October 2019
01/10/2019 - 14:00 -
Replimune to Present at Chardan’s 3rd Annual Genetic Medicines Conference
01/10/2019 - 14:00 -
Ziopharm Oncology Announces FDA Clearance of IND for Rapid Personalized Manufacture of CD19-specific CAR-T
01/10/2019 - 14:00 -
BioCardia Initiates Commercial Release of AVANCE Steerable Introducer Designed to Enhance Physician Control for Complex Cardiac Procedures
01/10/2019 - 14:00 -
Conformis and Stryker Execute Development, License and Distribution Agreements
01/10/2019 - 14:00 -
Xeris Pharmaceuticals Appoints Mark Thierer to Board of Directors
01/10/2019 - 14:00 -
BeyondSpring Presents Novel Trial Design for DUBLIN-3 Study BPI-2358-103 at ESMO Congress 2019
01/10/2019 - 14:00 -
Lantern Pharma and National Cancer Institute Partner to Aid Precision Oncology Research and Treatments
01/10/2019 - 14:00 -
Cocrystal Pharma Announces Abstract Accepted for Poster Presentation at 26th International Symposium on Hepatitis C Virus and Related Viruses
01/10/2019 - 14:00 -
BioDelivery Sciences Announces Significant Additional Insurance Coverage for both BELBUCA® and Symproic®
01/10/2019 - 14:00 -
TYME Presented Updated Data at ESMO 2019 from SM-88 Phase II Prostate Cancer Study Demonstrating Encouraging Clinical Benefit in Patients with Recurrent Prostate Cancer
01/10/2019 - 14:00 -
Align Technology to Announce Third Quarter 2019 Results on October 23, 2019
01/10/2019 - 14:30
Pages